Atonarp raises USD 33 million in oversubscribed Series C funding round

• The funding round has brought over 5 new investors to the company.
   
• The funding raised would be primarily used to support the company’s product prototyping and managing and advertising in 2020.

Tokyo headquartered Atonarp Incorporation reportedly announced raising USD 33 million in an oversubscribed Series C funding round. Supposedly, this round introduced in over 5 new investors to the company including the Japan Post Investment Corp., SBI Investment Co., and some of the major medical equipment manufacturing companies.

It has been claimed that since over 2014, the company has raised over more than USD 61 million in 3 rounds of equity financing in hunt of its vision of bringing in an advanced level of process monitoring and healthcare diagnostics through its advanced AI-dependent platforms of mass spectrometry & optical spectroscopy.

The optical spectroscopy is expected to offer pain-free blood testing with lab-quality precision but with real-time actionable information. Speculation has it that the Series C funding will augment the company's balance sheet and aid the ongoing product prototyping and management into the healthcare industry.

Prakash Murthy, the Chief Executive Officer at Atonarp reportedly stated that with the company’s latest innovative engineering development, it has been perfectly positioned to meet the product roadmap expectations by 2020. Further, the company has continued to execute at a speedy pace towards its vision of unsettling the old time-consuming, painful and expensive healthcare diagnostics. Additionally, the company is honored to welcome onboard the 5 long-term investors to support its vision of growth.

Meanwhile, the Deputy General Manager of Investment Department, SBI Investment, Yusuke Matsumoto cited that Atonarp has not only demonstrated its potential in the healthcare market with the help of innovative technology, but the inclusion of AI with data analytics model being build, has the latency to produce personalized health portfolios for many people.

For the records, 2009 established Atonarp Incorporation is a Molecular Diagnostics company which is reinventing the applications of sensing and diagnostic equipment in order to produce real-time actionable data.

Source credit: https://finance.yahoo.com/news/atonarp-inc-announces-33-million-230000269.html